Clinical trial CORIOLAN
CORIOLAN : Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advanced colorectal cancer
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Academic trial | Oui |
| Sponsor | Institut Jules Bordet |
| EudraCT Identifier | 2011-00628-021 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01591590 |
| Inclusion criteria | colorectal cancer, metastatic or unresectable and for which standard treatments do not exist or are no longer effective.All standard chemotherapy agents (fluoropyrimidines, irinotecan and oxaliplatin) and monoclonal antibodies (bevacizumab, cetuximab an |
| Last update |